United States Patent 5,928,643: Claim Validity, Scope, and Competitive Patent Landscape
United States Patent 5,928,643 claims methods to initiate T-cell activation by administering engineered LFA-3 polypeptides. The patent’s enforceable reach hinges on (i) the LFA-3 amino-terminal segment (residues 1-92) and (ii) the nature of the attached partner domain, including an immunoglobulin hinge plus CH2/CH3 constant domains or an Fc region recognized by protein A, plus a plasmid-encoded embodiment. The landscape is dominated by later developments in recombinant T-cell co-stimulation (notably LFA-3/CD58 axis biology), engineered Ig-Fc fusions, and broad immunotherapy composition and method filings.
What do the claims actually cover? (Claim-by-claim dissection)
Claim 1: LFA-3(1-92) fused to an immunoglobulin fragment with hinge + CH2 + CH3
Claim 1 preamble
- “A method of initiating T-cell activation”
- “administering to a population of T cells” a specified polypeptide
Core structural requirement
- LFA-3 amino terminal amino acids 1-92 joined to “a protein or polypeptide other than LFA-3”
- The attached partner must comprise a portion of hinge, C(H)2 and C(H)3 constant domains of an immunoglobulin
Functional requirement
- “joined to” is structural; the claim also ties to “initiating T-cell activation,” which is an intended-use/biological effect constraint tied to the administered polypeptide.
Critical scope notes
- The claim does not require a specific immunoglobulin isotype in the text you provided. However, the next claims are narrower (IgG1 and protein A recognition). That makes Claim 1 the broad backbone for hinge-CH2-CH3-containing fusions.
Claim 2: LFA-3(1-92) + human IgG1 Fc fragment recognized by protein A
Claim 2 adds narrowing limitations
- LFA-3(1-92) [SEQ ID NO:1]
- fused with “a portion of an Fc region of a human immunoglobulin IgG1”
- the Fc portion must be “sufficient to be recognized by protein A”
Critical scope notes
- This “protein A recognition” is a functional structural proxy. It tends to be satisfied by Fc regions that retain the protein A binding epitope(s).
- Claim 2 is narrower than Claim 1 because it anchors to human IgG1 and an Fc functional property.
Claim 3: Fc hinge capable of forming intermolecular disulfide bonds
Claim 3 further narrows Claim 2
- Fc region must include a hinge region that can form intermolecular disulfide bonds
Critical scope notes
- This targets Fc designs that dimerize via hinge disulfides (or contain intact hinge cysteines). It excludes hinge-modified Fc scaffolds that disrupt intermolecular bonding.
Claim 4: plasmid pSAB 152 ATCC 68720 encoding the polypeptide
Claim 4 type
- “A method ... comprising administering ... a polypeptide encoded by a DNA sequence contained in plasmid pSAB 152 ATCC Accession Number 68720.”
Critical scope notes
- This is a classic “DNA source defines the protein” claim format. In infringement analysis, it shifts the key question to whether an accused polypeptide is encoded by that plasmid sequence (or its contained DNA sequence).
- If a competitor uses a different expression cassette that yields the same protein, Claim 4 may not read unless the claim construction treats encoding equivalence as covered. Many courts require literal encoding match to the claimed DNA sequence contained in the specific plasmid.
What are the claim “pressure points” for validity and enforcement?
1) “Amino terminal amino acids 1-92 of LFA-3” is a specific sequence boundary but still leaves design space
- Fixing LFA-3 to residues 1-92 narrows the LFA-3 component, but it does not specify:
- exact fusion junction residue,
- linker composition,
- whether additional LFA-3 residues are excluded,
- whether the fusion partner is exactly hinge + CH2 + CH3 or can be partial variants.
2) IgG Fc language is broad for Claim 1 and narrowed for Claims 2 and 3
- Claim 1: “portion of hinge, CH2 and CH3 constant domains” can cover a range of Fc fragments (including truncated Fc fusions that retain CH2/CH3).
- Claim 2: “human IgG1 Fc ... recognized by protein A” can be met by many Fc variants that preserve protein A binding.
- Claim 3: “hinge capable of forming intermolecular disulfide bonds” limits to Fc scaffolds with hinge disulfide potential, which may be avoided by hinge mutations.
3) Method claims risk obviousness attacks if co-stimulatory fusions were known
- T-cell activation via LFA-3 and immunoglobulin Fc fusions is likely to have antecedent art because:
- LFA-3/CD2-related co-stimulation is well established in immunology,
- Fc fusions for immunotherapy are a standard recombinant strategy.
Your strongest patent-risk assumption (based purely on claim content, not external prosecution history) is that a reviewer could characterize the claimed design as routine engineering:
- use the biologically active LFA-3 segment,
- fuse to a stable dimeric Fc scaffold,
- administer for activation.
4) “Protein A recognition” can be a novelty and prior-art issue
- If prior art Fc fragments and fusions use IgG1 Fc fragments known to bind protein A, the novelty hinges on whether the combination with LFA-3(1-92) was not disclosed.
- If the LFA-3 portion was already disclosed with Fc fusions, the functional “protein A recognition” may not rescue novelty.
Competitive patent landscape: how the field is likely mapped around these claims
Given the claim architecture, the most relevant competitor clusters are:
1) LFA-3/CD58 axis co-stimulation and engineered ligand fusions
- Patents and publications covering engineered immunoadhesins or co-stimulatory molecules that engage LFA-3/CD58 or CD2-related pathways.
- Key variables:
- ligand domain length (e.g., fragments vs full-length),
- fusion scaffolds (Ig domains, Fc, albumin-binding, etc.),
- multimerization/dimerization.
2) IgG1 Fc fusion scaffolds and protein A binding
- Dense patent coverage across:
- Fc truncations (Fc fragments vs full-length Ig),
- hinge engineering (disulfide versus disrupted hinge),
- protein A purification-compatible Fc designs.
- Infringement sensitivity:
- Claim 2 can be met by most standard IgG1 Fc fragments.
- Claim 3 is the escape point because hinge disulfide compatibility can be altered.
3) DNA plasmid-specific embodiments
- Claim 4 is narrower but also sits in a more brittle enforcement position:
- if competitors use different plasmids but express the same polypeptide, Claim 4 may not reach,
- if competitors license or design around plasmid sequences, it reduces Claim 4 leverage.
4) Method-of-use claims in immunotherapy
- Broad filings on “initiating T-cell activation” via engineered binding proteins are numerous.
- These can create overlap for later claims even if they do not replicate the exact LFA-3-Fc architecture.
Where would infringement most likely land? (Scenario mapping to claim elements)
A. Direct infringement under Claim 1
An accused polypeptide would need:
- LFA-3 N-terminus residues 1-92 present as a contiguous segment,
- fused to a partner containing hinge + CH2 + CH3 constant domains of an immunoglobulin,
- administered to T cells with an effect that qualifies as “initiating T-cell activation.”
Typical design that matches well
- LFA-3(1-92)-Fc (Fc fragment with hinge + CH2 + CH3).
B. Direct infringement under Claim 2
Adds:
- Fc must be IgG1 and “sufficient to be recognized by protein A.”
Design that matches
- standard IgG1 Fc or Fc fragments that retain protein A binding.
C. Avoidance under Claim 3
A competitor can attempt to design around by:
- using hinge mutations that prevent intermolecular disulfide formation,
- using alternate multimerization strategies instead of hinge disulfide-linked dimers.
D. Claim 4 enforcement is narrowest
- If a competitor expresses the protein from a different plasmid or a different contained DNA sequence, Claim 4 can fail even if the expressed protein is identical.
Patent landscape risk and opportunity: how claim scope interacts with common design-arounds
Design-around levers
1) Change Fc hinge disulfides (target Claim 3)
- If hinge disulfides are altered, a competitor can reduce or eliminate coverage under Claim 3 while leaving Claims 1-2 potentially still implicated.
2) Change Ig isotype or protein A binding compatibility (target Claim 2)
- Use non-IgG1 Fc scaffolds or Fc variants engineered to reduce protein A binding.
- This is a direct way to reduce Claim 2 fit. Claim 1 could still apply if the hinge + CH2 + CH3 constant domains remain present in an immunoglobulin fragment.
3) Avoid LFA-3 residues 1-92 exact boundary
- If the biologically active segment is extended or shortened beyond 1-92, literal infringement becomes harder.
4) Use a different plasmid DNA source (target Claim 4)
- Even with the same polypeptide outcome, the “encoded by DNA sequence contained in plasmid pSAB 152” element can be avoided if the DNA sequence differs.
Enforcement leverage points
- Claims 1-3 are composition-defined (polypeptide architecture) coupled to a method effect (T-cell activation). If the competitor makes the same fusion, infringement posture improves.
- Claim 4 is leverageable only if competitors use the same plasmid source or DNA sequence.
Critical analysis of novelty plausibility from the claim language alone
Without prosecution history and the full spec, the claim language itself suggests the following:
-
The combination of a known T-cell activation axis ligand fragment with a standard Fc stabilization/assembly mechanism is likely to face:
- obviousness pressure,
- anticipation pressure if prior art already disclosed LFA-3(1-92)-Fc (or LFA-3 fragment)-Fc constructs.
-
Claim 2’s “protein A recognition” is often inherent to IgG1 Fc fragments used in routine recombinant antibody production and therefore may not add patentable distinction unless the prior art used different scaffolds or different LFA-3 fragments.
-
Claim 3 is potentially more defensible because hinge disulfide formation is a design feature, but it is also a known engineering variable in Fc domain design. If the art used intact hinges in Fc fusions, it may still be covered.
-
Claim 4 is the most legally specific due to the plasmid identifier and ATCC accession, but it is also the most vulnerable to practical design-arounds by plasmid replacement.
Key Takeaways
- Claim architecture centers on LFA-3(1-92) fused to immunoglobulin hinge/CH2/CH3 (Claims 1-3) or plasmid-encoded polypeptide from pSAB 152 (Claim 4).
- Scope is broad in Claim 1 (hinge + CH2 + CH3 from an immunoglobulin as the partner fragment) and narrows in Claims 2 and 3 (human IgG1 Fc with protein A recognition; hinge disulfide-capable hinge).
- The strongest practical infringement risk for competitors is designs using IgG1 Fc fragments with protein A binding plus an intact hinge.
- The strongest design-around is altering the Fc hinge to break intermolecular disulfide linkage (Claim 3) and/or using an Fc scaffold not recognized by protein A (Claim 2).
- Claim 4 is brittle because it ties to a specific plasmid DNA source; switching expression constructs can reduce exposure.
FAQs
1) Is Claim 1 broader than Claim 2?
Yes. Claim 1 only requires hinge + CH2 + CH3 constant domains of an immunoglobulin fragment; Claim 2 further requires human IgG1 Fc sufficient for protein A recognition.
2) What is the most direct design-around to weaken Claim 3?
Mutating or replacing the Fc hinge so it cannot form intermolecular disulfide bonds.
3) Does Claim 4 cover a polypeptide if it is identical but encoded from a different plasmid?
The claim language ties coverage to “a DNA sequence contained in plasmid pSAB 152” with a specific ATCC accession; a different plasmid source can avoid the “encoded by” limitation.
4) Is “protein A recognition” likely to be satisfied by standard IgG1 Fc fragments?
Yes, standard IgG1 Fc fragments used in recombinant antibody formats typically retain protein A binding; that makes Claim 2 dependent on whether the LFA-3(1-92)-Fc combination was disclosed in prior art.
5) What element most strongly constrains the LFA-3 portion?
The fixed boundary to “amino terminal amino acids 1-92 of LFA-3,” which limits the claim to that N-terminal segment rather than an arbitrary LFA-3 fragment.
References (APA)
[1] U.S. Patent No. 5,928,643.
